Welcome to the web version of STAT’s popup newsletter, AACR in 30 seconds, your quick overview of the happenings at the American Association of Cancer Researchers’ annual meeting.
This marks the final edition of our special newsletter. We hope you’ve gained as much insight as we have. If you’re not yet a STAT+ subscriber, consider joining us! There’s currently a 60% discount on annual subscriptions.
Thank you for being with us on this journey.
Overcoming Resistance and RevMed’s New Drug
If you missed it, Revolution Medicines attracted a full house during their sessions yesterday. While much of the media spotlighted the data on daraxonrasib for frontline pancreatic cancer, the company also introduced another promising compound, RM-055. CEO Mark Goldsmith presented it as part of an innovative class of “catalytic inhibitors,” capable of removing a phosphate from GTP-RAS—the active form of RAS—thereby deactivating the protein.
This development sparked significant interest due to its potential in combating cancer resistance. A common resistance strategy involves the amplification of mutant RAS, which saturates the cell with the oncoprotein, diminishing the inhibitor’s effectiveness. RM-055 may offer a strategic advantage by deactivating multiple mutant RAS proteins, potentially advancing the fight against RAS-dependent cancers.
To delve deeper into this story, visit STAT+ for the comprehensive article…
